↓ Skip to main content

Dove Medical Press

Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation

Overview of attention for article published in Clinical, Cosmetic and Investigational Dermatology, September 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
14 Mendeley
Title
Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation
Published in
Clinical, Cosmetic and Investigational Dermatology, September 2015
DOI 10.2147/ccid.s90542
Pubmed ID
Authors

Kara Capriotti, Joseph A Capriotti

Abstract

Nail changes associated with chemotherapy in general, and particularly with taxane and epidermal growth factor receptor inhibitor-based regimens, are common presentations in our clinical population. Currently, there are no consensuses about therapies supported by clinical trials nor are there any US Food and Drug Administration-approved treatments for this indication. A 42-year-old woman with stage 2A breast cancer presented to our clinic with chemotherapy-induced paronychia. Symptoms were severe enough that cessation of chemotherapy was being considered. The patient's chemotherapy regimen included doxorubicin, cyclophosphamide, and docetaxel. The topical povidone-iodine/dimethylsulfoxide system is very effective in alleviating the signs and symptoms of severe paronychia associated with chemotherapy. This novel combination warrants further investigation in randomized, controlled trials to further elucidate its clinical utility.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 21%
Other 2 14%
Lecturer 1 7%
Professor 1 7%
Student > Doctoral Student 1 7%
Other 2 14%
Unknown 4 29%
Readers by discipline Count As %
Medicine and Dentistry 7 50%
Psychology 2 14%
Biochemistry, Genetics and Molecular Biology 1 7%
Unknown 4 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2015.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from Clinical, Cosmetic and Investigational Dermatology
#807
of 905 outputs
Outputs of similar age
#237,476
of 276,791 outputs
Outputs of similar age from Clinical, Cosmetic and Investigational Dermatology
#15
of 18 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 905 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,791 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.